Plasmodium falciparum asexual blood stage (P. falciparum ABS)

Plasmodium falciparum asexual blood stages refer to the intraerythrocytic phase of the malaria parasite's life cycle, which is the primary driver of clinical disease and pathology in humans [CDC]. This cycle begins when merozoites invade red blood cells, progressing through the ring, trophozoite, and schizont stages before causing cell rupture and the release of new merozoites [Nature Reviews Microbiology]. During this period, the parasite extensively remodels the host cell and degrades hemoglobin to obtain nutrients, creating several metabolic vulnerabilities [Cell Host & Microbe]. Most frontline antimalarial therapies, including artemisinins and quinolines, specifically target these stages to rapidly reduce parasitemia and alleviate symptoms [WHO]. The parasite's ability to sequester in the microvasculature during the trophozoite and schizont stages contributes to severe complications like cerebral malaria [PubMed]. However, the development of resistance to these drugs, particularly artemisinin-based combination therapies, poses a major threat to global malaria control efforts [Trends in Parasitology].

Other names

Erythrocytic stageIntraerythrocytic cycleBlood-stage malariaPlasmodium falciparum asexual blood stages

Drugs targeting this stage act through various mechanisms: quinolines (e.g., chloroquine) inhibit the biocrystallization of toxic heme into non-toxic hemozoin [PubChem]; artemisinins generate reactive oxygen species that damage parasite proteins and lipids [Trends in Parasitology]; antifolates (e.g., pyrimethamine) inhibit DNA synthesis by targeting dihydrofolate reductase [NIH]; and atovaquone disrupts the mitochondrial electron transport chain [PubMed].